Ziglim-M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose utilization. The combination of these agents offers complementary mechanisms of action, facilitating effective blood glucose regulation in patients inadequately controlled by diet and exercise alone. Ziglim-M 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to the sulfonylurea component. Caution is advised in patients with cardiovascular disease or those undergoing radiologic studies involving iodinated contrast agents. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy to ensure safety and efficacy.